TIDMAG99 TIDMGSK

RNS Number : 9235Y

GlaxoSmithKline Capital PLC

09 September 2022

Issued: 9 September 2022, London UK

GlaxoSmithKline Capital plc Publication of Base Prospectus

GlaxoSmithKline Capital plc today announced that the following base prospectus dated 7 September 2022 has been approved by the Financial Conduct Authority and is available for viewing:

GSK plc, GlaxoSmithKline Capital plc, GSK Capital BV and GSK Capital KK GBP20,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the UK Listing Authority's National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS). The base prospectus will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

For further information, please contact:

Company Secretary

GSK plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

company.secretary@gsk.com

Enquiries:

 
 UK Media enquiries:         Tim Foley        +44 (0) 20 8047     (London) 
                                               5502 
 European Analyst/Investor   Nick Stone       +44 7717 618 834    (London) 
  enquiries: 
                              James Dodwell    +44 7881 269 066    (London)

BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS

Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base p rospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company

Registered in England & Wales:

No. 2258699

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PDIEAPNNEEXAEEA

(END) Dow Jones Newswires

September 09, 2022 04:11 ET (08:11 GMT)

Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gsk Charts.